Gökhan Sami Kılıç

Dr. Gökhan Sami Kılıç


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2008 in European Journal Of Cancer Prevention
Verified
Journal Article
Closed access
MBMelih C. Boruban
Melih C. Boruban
KAKadri Altundag
Kadri Altundag
GKGökhan Sami Kılıç
Gökhan Sami Kılıç
JBJosef Blankstein
Josef Blankstein
Controversies are still seen in the histological differential diagnosis of hyperplasia and well-differentiated endometrial carcinoma. Prediction of endometrial cancer in patients with hyperplasia with atypia, with the available markers has not been reliable yet. Hence these patients require more attention in the clinical management. Endometrial hyperplasia is proliferation of endometrial glands resulting in a higher gland : stroma ratio. Cytological atypia, which may progress to or co-exist with endometrial cancer and other pathological changes, result from estrogen stimulation unopposed by progesterone. Biomarkers whose expression is altered in cases of endometrial hyperplasia or cancer such as progesterone receptor, insulin-like growth factor I, retinaldehyde dehydrogenase type II, and secreted frizzled-related protein 4, seem to be promising to use as early-stage tumor markers. Mutation of PTEN is present in 83% of endometrial adenocarcinoma cases, making it the most frequent early molecular genetic alteration in type 1 endometrial tumors, which are generally associated with hyperplasia. p53 gene mutation is not found in endometrial hyperplasia, but researchers have detected this mutation in 20% of cases of endometrial carcinoma and 90% of cases of serous endometrial tumors. Cyclooxygenase-2 is important in tumorogenic transformation of hyperplasia. Expression of cyclooxygenase-2 decreases apoptosis, increases angiogenesis, and is related to invasiveness. Cyclooxygenase-2 expression increases significantly in cases of well-differentiated endometrial adenocarcinoma. Prostaglandin E2 is known to regulate aromatase gene expression and is the product of cyclooxygenase-2. The data about aromatase inhibitors are promising; in breast cancer patients, treatment with tamoxifen induces uterine abnormalities as early as 3 months after the initiation of therapy. In contrast, these abnormalities are not seen in patients who receive aromatase inhibitors and switched therapy after tamoxifen withdrawal may reverse tamoxifen-associated endometrial thickening.

1 January 2008 in Reproductive BioMedicine Online
Verified
Journal Article
Closed access
BGBilgin Gurates
Bilgin Gurates
CPCem Parmaksiz
Cem Parmaksiz
GKGökhan Sami Kılıç
Gökhan Sami Kılıç
HCHusnu Celik
Husnu Celik
SKSelahattin Kumru
Selahattin Kumru
MSMehmet Simsek
Mehmet Simsek

1 April 2000 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
SBSerdar E. Bulun
Serdar E. Bulun
KZKhaled M. Zeitoun
Khaled M. Zeitoun
GKGökhan Sami Kılıç
Gökhan Sami Kılıç

28 November 2015 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
ARAna M. Rodriguez
Ana M. Rodriguez
MAMehmet R. Asoglu
Mehmet R. Asoglu
MSMuhammet Erdal Sak
Muhammet Erdal Sak
ATAlai Tan
Alai Tan
MBMostafa A. Borahay
Mostafa A. Borahay
GKGökhan Sami Kılıç
Gökhan Sami Kılıç

1 January 2012 in Journal of Cancer
Verified
Journal Article
Open access
MKMarwa Kamel
Marwa Kamel
SSsamia shouman
samia shouman
MEMahmoud El-Merzebany
Mahmoud El-Merzebany
GKGökhan Sami Kılıç
Gökhan Sami Kılıç
TVTimothy Veenstra
Timothy Veenstra
SSSalama Salama
Salama Salama
Tumor necrosis factor-alpha (TNF-α) is a proinflammatory cytokine that has been linked to breast cancer development. Estrogen metabolic pathway is also involved in breast carcinogenesis and DNA adducts formation. In this study we investigated the effect of TNF-α on the estrogen metabolic pathway in MCF-7, a breast cancer cell line. Capillary liquid chromatography/mass spectrometry (LC/MS) and High performance liquid chromatography (HPLC) were used for analysis of estrogen metabolites and estrogen-DNA adducts levels respectively. Reporter gene assay, Real time reverse transcription polymerase chain reaction (real time RT-PCR) and Western blot were used to assess the expression of estrogen metabolizing genes and enzymes. TNF-α significantly increased the total EM and decreased the estrone (E1) / 17-β estradiol (E2) ratio. Moreover, it altered the expression of genes and enzymes involved in E2 activation and deactivation pathways e.g. Cytochrome P-450 1A1 (CYP1A1), Cytochrome P-450 1B1 (CYP1B1), Catechol-O-methyl transferase (COMT) and Nicotinamide adenine dinucleotide phosphate-quinone oxidoreductase 1 (NQO1). In addition, there were increased levels of some catechol estrogens e.g. 4-hydroxy-estrone (4-OHE1) and 2-hydroxyestradiol (2-OHE2) with decreased levels of methylated catechols e.g. 2-methoxy estradiol (2-MeOE2). DNA adducts especially 4-OHE1-[2]-1-N3 Adenine was significantly increased. TNF-α directs the estrogen metabolism into more hormonally active and carcinogenic products in MCF-7. This may implicate a new possible explanation for inflammation associated breast cancer.

7 October 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SSSalama A. Salama
Salama A. Salama
MKMarwa W. Kamel
Marwa W. Kamel
SBShaleen Botting
Shaleen Botting
SSSana M. Salih
Sana M. Salih
MBMostafa A. Borahay
Mostafa A. Borahay
CDConcepcion R. Diaz-Arrastia
Concepcion R. Diaz-Arrastia
Development of optimal medicinal treatments of uterine leiomyomas represents a significant challenge. 2-Methoxyestradiol (2ME) is an endogenous estrogen metabolite formed by sequential action of CYP450s and catechol-O-methyltransferase (COMT). Our previous study demonstrated that 2ME is a potent antiproliferative, proapoptotic, antiangiogenic, and collagen synthesis inhibitor in human leiomyomas cells (huLM). Our objectives were to investigate whether COMT expression, by the virtue of 2ME formation, affects the growth of huLM, and to explore the cellular and molecular mechanisms whereby COMT expression or treatment with 2ME affect these cells. Our data demonstrated that E2-induced proliferation was less pronounced in cells over-expressing COMT or treated with 2ME (500 nM). This effect on cell proliferation was associated with microtubules stabilization and diminution of estrogen receptor α (ERα) and progesterone receptor (PR) transcriptional activities, due to shifts in their subcellular localization and sequestration in the cytoplasm. In addition, COMT over expression or treatment with 2ME reduced the expression of hypoxia-inducible factor -1α (HIF-1 α) and the basal level as well as TNF-α-induced aromatase (CYP19) expression. COMT over expression or treatment with 2ME stabilize microtubules, ameliorates E2-induced proliferation, inhibits ERα and PR signaling, and reduces HIF-1 α and CYP19 expression in human uterine leiomyoma cells. Thus, microtubules are a candidate target for treatment of uterine leiomyomas. In addition, the naturally occurring microtubule-targeting agent 2ME represents a potential new therapeutic for uterine leiomyomas.